The FDA approved Novo Nordisk’s high‑dose Wegovy (7.2 mg) under a commissioner voucher program that expedited the review to roughly 54 days. The clearance expands dosing options for adults with obesity and follows Novo’s policy commitments to the White House on pricing. The higher‑dose formulation produced greater weight loss in trials and offers Novo a commercial lever as it competes with Eli Lilly’s more efficacious rival. The voucher program—created to accelerate approvals deemed in the national interest—has drawn political and industry scrutiny for rapid timelines and perceived favoritism. The Wegovy HD approval gives Novo a clinical and marketing counterweight in the tight GLP‑1/obesity marketplace and may intensify pricing and formulary negotiations across payers and providers. Clarification: The commissioner’s voucher program shortens FDA review windows for select applications but is controversial due to its discretionary allocation.